# Takeda: Phase 3 study closed enrollment, 800 enrolled (Dengue Fever)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Takeda |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) |
| NCT ID | NCT06579755 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Dengue Fever |
| Intervention types | biological, other |
| Target enrollment | 800 |
| Site countries | Argentina, Brazil, Singapore, Thailand |
| Posted | 2024-08-30 |
| Planned start | 2026-01-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-22 |
| Last update posted | 2026-09-22 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 800 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06579755). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.